LRP11, also known as low density lipoprotein receptor-related protein 11, is involved in multiple biological processes. It plays a role in lipid metabolism-related pathways as it has been associated with cholesterol homeostasis, and is important in tumor-related biological functions and immune-related mechanisms [2,3].

In tumor-related research, LRP11 has been found to have diverse effects. In prostate cancer, it activates β-catenin to induce PD-L1 expression, which may help tumor cells evade immune attack [2]. In hepatocellular carcinoma, knockdown of LRP11 reduces lipid accumulation and decreases key lipid metabolism markers, suggesting its role in facilitating lipid metabolism and malignancy in this cancer type [3]. In cervical cancer, it is highly expressed and acts as a risk prognostic factor, and is involved in multiple tumor-malignant pathways, with high-expressing patients potentially having an immune-desert tumor microenvironment and drug resistance [4]. In the context of immunotherapy, LRP11 promotes stem-like T cells via MAPK13-mediated TCF1 phosphorylation, enhancing anti-PD1 immunotherapy. LDL-induced LRP11 activation can increase stem-like T cells and enhance antitumor immunity [1].

In conclusion, LRP11 is crucial in lipid metabolism and tumor-related biological processes. Its role in promoting stem-like T cells has implications for immunotherapy, and its functions in various cancers, such as prostate, hepatocellular, and cervical cancers, make it a potential therapeutic target in oncology research.